Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
  • Added to PubMed Health

    clear
    • Custom range...

Results: 5

Co‐formulated abacavir‐lamivudine‐zidovudine for treating HIV infection and AIDS

The primary objective of this review was to evaluate the antiviral efficacy of co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We identified 15 potentially eligible studies, four of which met our inclusion criteria. Our findings indicate that co‐formulated abacavir‐lamivudine‐zidovudine remains a viable option for initiating antiretroviral therapy, especially in HIV‐infected patients with pre‐existing hyperlipidaemia and those who do not tolerate ritonavir.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV

Regimen simplification can be defined as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements. Many patients on suppressive antiretroviral therapy may be considered candidates for a simplification strategy and, among them, those who have achieved virologic suppression. We have reviewed clinical trials evaluating the efficacy and safety of abacavir‐containing triple nucleoside combination as a simplification therapy in HIV‐infected adult patients treated with a Protease‐Inhibitor (PI)‐containing regimen and  with undetectable viral load. Patients on a PI‐containing regimen had three possibilities: continue the PI regimen or switch to a simplification maintenance regimen with triple nucleoside combination (abacavir‐zidovudine‐lamivudine) or with non‐nucleoside (efavirenz or nevirapine) containing regimens. The review included 8 RCTs and 1675 HIV infected patients. Simplification with triple nucleoside regimen showed an overall failure rate comparable to that of  continuing  PI regimen or  to simplification with non‐nucleoside regimens. Rates of failure due to adverse events with triple nucleoside combinations were lower compared to controls, but the difference was not statistically significant. By contrast, rates of virologic failures   were more frequent with  triple nucleoside combination that with PI or NNRTI, but in both the comparisons the differences were  not statistically significant. Simplification with abacavir had a favourable and significant impact on lipid metabolism compared to control group. Simplification with triple nucleoside regimens should be still considered for individuals who are unable to tolerate or have contraindications to NNRTI or PI based regimens

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2013

Therapy for treating HIV infection in pregnant women who require treatment for their own health

Pregnant human immunodeficiency virus‐infected (HIV)‐infected women often need treatment with antiretroviral therapy (ART) for their own health. Mother‐to‐child transmission (MTCT) is the most common way that children worldwide become HIV infected. Treatment of HIV‐infected pregnant women with ART decreases the risk of HIV MTCT. It is possible to decrease the risk of MTCT to 1‐2% with the use of antiretroviral medications, caesarean section before labour begins, and avoiding breastfeeding. When women who require HIV treatment for the benefit of their own health become pregnant, we need to know the most effective therapy, the impact of the drug on the MTCT of HIV, and what the potential complications of the therapy might be for both the mother and her unborn child.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

HIV infection: What are the advantages or disadvantages of rilpivirine (Edurant)?

Rilpivirine was approved as a single agent under the trade name Edurant in Germany in November 2011 for adults infected with HIV type 1. It is an option for people who have not yet used any other medications against HIV and in whom not more than 100,000 viral components can be detected per milliliter of blood.

Informed Health Online [Internet] - Institute for Quality and Efficiency in Health Care (IQWiG).

Version: October 25, 2012

Antiretrovirals for reducing the risk of mother‐to‐child transmission of HIV infection

At the end of 2009, 2.5 million children under the age of 15 years were estimated to be living with HIV/AIDS (WHO 2011). The majority of these children acquired their infections as a result of mother‐to‐child transmission during pregnancy, labor, or breastfeeding. Antiretroviral drugs administered to the HIV‐infected mother and/or to her child during pregnancy, labor, or breastfeeding can reduce mother‐to‐child transmission of HIV. The objective of this review is to determine whether a regimen of antiretroviral drugs leads to a significant reduction in HIV transmission during pregnancy and labor without serious side‐effects.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...